Sutro Biopharma (STRO) Net Cash Flow Growth (3y) (2020 - 2025)
Powered by 
Analysis
Sutro Biopharma (STRO) Net Cash Flow Growth (3y) (2020 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 4.55% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 52.78% |
| 10 | Sutro Biopharma | 334.66 Mn | 170.32 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 46.00% |
| Sep 30, 2025 | -52.43% |
| Jun 30, 2025 | -41.62% |
| Mar 31, 2025 | -281.60% |
| Dec 31, 2024 | 281.84% |
| Sep 30, 2024 | 73.94% |
| Jun 30, 2024 | 254.49% |
| Mar 31, 2024 | 69.99% |
| Dec 31, 2023 | -27.83% |
| Sep 30, 2023 | -981.97% |
| Jun 30, 2023 | 99.37% |
| Mar 31, 2023 | -26.68% |
| Dec 31, 2022 | -92.03% |
| Sep 30, 2022 | 63.56% |
| Jun 30, 2022 | 107.62% |
| Mar 31, 2022 | 75.16% |
| Dec 31, 2021 | -26.07% |
| Sep 30, 2021 | -53.43% |
| Jun 30, 2021 | -68.74% |
| Mar 31, 2021 | -113.78% |